Use of glucagon-like peptide-1 receptor agonists and bone fractures: A meta-analysis of randomized clinical trials

Journal of Diabetes

Volumn 6, Issue 3, 2014, Pages 260-266

  Mabilleau, Guillaume ^a   Mieczkowska, Aleksandra ^a   Chappard, Daniel ^a  

^a UNIVERSITÉ D'ANGERS   (France)

Author keywords

Bone fractures; Glucagon like peptide 1 receptor agonists; Meta analysis; Type 2 diabetes mellitus

Indexed keywords

ALBIGLUTIDE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; SEMAGLUTIDE; TASPOGLUTIDE; VILDAGLIPTIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; PEPTIDE; VENOM;

ARTICLE; BODY MASS; EMBASE; FRACTURE; HUMAN; INCIDENCE; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOLYSIS; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; AGONISTS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; FRACTURES, BONE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, GLUCAGON; TREATMENT OUTCOME; VENOMS;

EID: 84898602225     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12102     Document Type: Article

References (33)

1. Mojsov S, Weir GC, Habener JF. Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987; 79: 616-619.
2. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993; 91: 301-307.
3. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001; 50: 609-613.
4. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia. 2002; 45: 1111-1119.
5. de Liefde I, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: The Rotterdam Study. Osteoporos Int. 2005; 16: 1713-1720.
6. Schwartz AV, Vittinghoff E, Bauer DC etal. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011; 305: 2184-2192.
7. Mabilleau G, Mieczkowska A, Irwin N, Flatt PR, Chappard D. Optimal bone mechanical and material properties require a functional GLP-1 receptor. J Endocrinol. 2013; 219: 59-68.
8. Yamada C, Yamada Y, Tsukiyama K etal. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology. 2008; 149: 574-579.
9. Nuche-Berenguer B, Moreno P, Esbrit P etal. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int. 2009; 84: 453-461.
10. Nuche-Berenguer B, Moreno P, Portal-Nunez S, Dapia S, Esbrit P, Villanueva-Penacarrillo ML. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept. 2010; 159: 61-66.
11. Bunck MC, Poelma M, Eekhoff EM etal. Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. J Diabetes. 2012; 4: 181-185.
12. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: A meta-analysis of randomized clinical trials. Diabetes Care. 2011; 34: 2474-2476.
13. Jadad AR, Moore RA, Carroll D etal. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996; 17: 1-12.
14. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000; 53: 1119-1129.
15. Liberati A, Altman DG, Tetzlaff J etal. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ. 2009; 339: b2700.
16. Kahn SE, Zinman B, Lachin JM etal. Rosiglitazone-associated fractures in type 2 diabetes: An Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008; 31: 845-851.
17. Lipscombe LL, Jamal SA, Booth GL, Hawker GA. The risk of hip fractures in older individuals with diabetes: A population-based study. Diabetes Care. 2007; 30: 835-841.
18. Nicodemus KK, Folsom AR, Iowa Women's Health Study. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 2001; 24: 1192-1197.
19. Schwartz AV, Sellmeyer DE, Ensrud KE etal. Older women with diabetes have an increased risk of fracture: A prospective study. J Clin Endocrinol Metab. 2001; 86: 32-38.
20. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA. 2007; 298: 194-206.
21. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35: 1364-1379.
22. Jensen LB, Quaade F, Sorensen OH. Bone loss accompanying voluntary weight loss in obese humans. J Bone Miner Res. 1994; 9: 459-463.
23. Langlois JA, Mussolino ME, Visser M, Looker AC, Harris T, Madans J. Weight loss from maximum body weight among middle-aged and older white women and the risk of hip fracture: The NHANES I epidemiologic follow-up study. Osteoporos Int. 2001; 12: 763-768.
24. Madsen LW, Knauf JA, Gotfredsen C etal. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology. 2012; 153: 1538-1547.
25. Hegedus L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP-1 and calcitonin concentration in humans: Lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab. 2011; 96: 853-860.
26. Gaudin-Audrain C, Irwin N, Mansur S etal. Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice. Bone. 2013; 53: 221-230.
27. Henriksen DB, Alexandersen P, Byrjalsen I etal. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone. 2004; 34: 140-147.
28. Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, Wilson PJ, Fraser WD. Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol. 2011; 11: 12.
29. Buse JB, Bergenstal RM, Glass LC etal. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes. Ann Intern Med. 2011; 154: 103-112.
30. Nauck M, Frid A, Hermansen K etal. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab. 2013; 15: 204-212.
31. Garber A, Henry RR, Ratner R etal. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011; 13: 348-356.
32. Gallwitz B, Bohmer M, Segiet T etal. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: A randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care. 2011; 34: 604-606.
33. Pratley R, Nauck M, Bailey T etal. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: A randomised, parallel-group, open-label trial. Int J Clin Pract. 2011; 65: 397-407.